Neurobiological Technologies Profit Margin

Neurobiological Technologies posts a profit margin of 39.19% as of September 2009. That compares with -125.91% in the prior-year period — up 131.1% year over year. That is above the Healthcare sector average of 10.58%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Neurobiological Technologies's profit margin was -125.91%. The latest reading is 39.19% — a 131.1% year-over-year increase (period ending September 2009). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 10.58% is typical. Neurobiological Technologies's 39.19% is higher that level. That is roughly 270.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Neurobiological Technologies's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 39.19% as of September 2009; use YoY and peer views to separate noise from signal.

Context for NTII's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 10.58%), and (3) consistency with growth and profitability. This page covers the first two; Neurobiological Technologies's other metric pages and overview cover the third.